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Although a number of animal models have been used to study the pathogenesis of lung disease, to date few studies have looked at
changed in the expression of cell cycle regulatory genes. We have studied the variation in the expression of p21, p53, p27 and PCNA in
bleomycin-induced lung fibrosis using animal mouse models using immuno-histochemistry and gene-expression analysis. No difference in
the p53, PCNA and p27 expressions were observed from the bleomycin-induced fibrosis when compared to saline-induced non-fibrotic
lungs. Although no difference in nuclear p21 expression was observed, the level of cytoplasmic p21 expression was found to be higher in
fibrotic lungs at day 14 after bleomycin injection. p21 expression was found to increase independent of p53 in fibrotic lungs at 14 days after
bleomycin induction.
D 2004 Elsevier Inc. All rights reserved.
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About 20% of the population worldwide die of lung-
related diseases, 17% of which are due to infections.
Pulmonary fibrosis affects about 100,000 people in the
United States.
Pulmonary interstitial fibrosis is defined as thickening
and stiffening of the lining of the air sacs (alveoli) of the
lungs causing progressive breathlessness (Cantin et al.,
1987; Crouch, 1990; Crystal et al., 1976, 1978). The
pathology of idiopathic pulmonary fibrosis (IPF) also
known as cryptogenic fibrosing alveolitis (CFA) shows an
initial alveolitis with persistent accumulation of inflamma-
tory cells including neutrophils, alveolar macrophages, and
lymphocytes in the lower respiratory tract. This is followed0014-4800/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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of type I alveolar epithelial cells and repopulation of the
epithelial cell surface by proliferating type II alveolar
epithelial cells, resulting in alterations in lung extracellular
matrix, fibroblast proliferation, and enhanced collagen
synthesis with the accumulation of excess connective tissue
in the lung (Cantin et al., 1987; Christensen et al., 1999;
Crouch, 1990; Crystal et al., 1976, 1978).
Various animal models have been used to study the
pathogenesis of lung disease, but to date few studies have
looked at changes in expression of cell cycle control genes in
these conditions. The p53 pathway was found to be involved
upon exposure of lung epithelial cells to either hyperoxia
(Barazzone et al., 1998; McGrath, 1998; O’Reilly et al., 1998)
or to a number of DNA-damaging agents and carcinogens
(Corroyer et al., 1996; Fujishita et al., 1995; Gadbois and
Lehnert, 1997; Guinee et al., 1996). The expression of p16
(Sabourin et al., 1998), p21 (Guinee et al., 1996; McGrath,
1998), Rb (Fujishita et al., 1995; Sabourin et al., 1998), c-jun
(Dolan et al., 1994; Haase et al., 1997), c-Fos (Haase et al.,thology 77 (2004) 231–237
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h (Lee and Rannels, 1998), BAX (Guinee et al., 1997), and
Bcl-2 (Guinee et al., 1997) was reported to be influenced by a
number of DNA-damaging agents and pollutants but the exact
mechanism is still unclear.
In this current paper, we would like to describe the
cellular pathology in these mouse lung models of the
diseases and try to understand the molecular mechanisms.
The aim of this paper is to study the variation in the
expression of p21, p53, p27, and PCNA and to describe the
cellular pathology in bleomycin-induced lung fibrosis using
animal mouse models. Understanding the cellular and
molecular pathology of the diseases hopefully would lead
to better and more effective diagnosis and treatment.Methods
Tissue sections
Mouse tissue sections of bleomycin-induced fibrosis and
saline treated (negative controls) were a kind gift of Prof.
Thomas Strandjord, Department of Pediatrics, Seattle, USA.
The method for bleomycin induction is described in
Hormuzudi et al. (1999). A total of six mice were used,
two bleomycin treated, two saline treated, and two untreated.
In brief, specific pathogen-free homozygous C57BL/6 mice,
8–10 weeks old (18–25 g in weight) were treated with 3.5
mU/g bleomycin sulfate in 2.33 Al/g sterile saline given via
transtracheal puncture under intraperitoneal Avertin anes-
thesia. Lungs were harvested at 14 days after instillation
overdose of intraperitoneal Avertin anesthesia and pulmo-
nary arteries perfused with PBS. The left lung was fixed by
intratracheal instillation of 4% paraformaldehyde in PBS at
30 cm H2O pressure for 2 h, then fixed overnight in 4%
paraformaldehyde in PBS at 4 8C and embedded in paraffin.
For the bleomycin-negative control, the mice were treated
with transtracheal sterile saline alone, 2.33 Al/g.
Antigen retrieval
Paraffin tissue sections were placed in xylene for 15 min.
The sections were then transferred in a series of alcohol
gradients from 100% to 74% to 64%, and then tap water for
10 min each.Table 1






p21 1/10 DAKO, Bucke,
UK
M7207
p53 1/100 Vector Lab,
Petersborough, UK
NCL-p53-CM5p
p27 1/200 Sigma, Dorset, UK P2092
PCNA 1/5000 Sigma, Dorset UK P8825DAKO antigen retrieval solution was prepared by diluting
1:100 with distilled water. A microwave dish was filled up
with antigen retrieval solution and preheated in a microwave
to boiling point. Slides that were dewaxed and rehydrated (as
described above) were placed in a plastic slide rack and
placed in a microwave dish containing the preheated antigen
retrieval solution and were microwaved three times for 5 min
each. The slides were allowed to cool for 30 min and then
were rinsed with H2O and equilibrated in TBS.
Immunohistochemistry
Slides were equilibrated in TBS for 5 min. The slides
were blocked with an adequate serum in which the
secondary antibody was raised. Primary antibody at a
concentration specified in Table 1 was applied for 2 h,
followed by three 5-min washes with TBST. Secondary
antibody was put on for 30 min then washed three times for
5 min each with TBST. An AlexaTM-conjugated secondary
antibody (diluted 1:200 in serum) was put on the slide and
incubated for 3 min. The slides were then washed three
times for 5 min each and mounted using DAKO fluorescent
mounting medium. The slides were then visualized under
confocal microscope (Leica DM IRBE, Leica Micosystem,
Cambridge, UK).
Three sections from each mouse were used for each gene
studied. Immunohistochemistry scoring was performed by
counting at least 100 cells at both the alveolar and
bronchiolar regions. The degree, intensity, and localization
of staining (i.e., either nuclear or cytoplasmic) were noted in
each cell. Cell counting was repeated at least three times on
each slide from both bleomycin- and saline-treated (control)
mice. Confocal microscopy and histopathology analyses
were carried out by both RB and DH independently.
Gene expression studies
The preparation of labeled cRNA, hybridization to
microarrays, and analysis of Genechip data were carried
out as previously described (Kaminski et al., 2000). Briefly,
total RNA was isolated from pooled lungs of six mice from
bleomycin-treated mice 7 or 14 days after treatment and
from mice 7 days after saline injection. A separate group of
control animals was sacrificed without any injection, and at
least three animals were included in each experimental
group. cRNA was prepared and hybridized to Genechip
array. The Genechip array was then analyzed using
Genechip 3.1 software (Affymetrix).Results
Histopathology
The injury following intratracheal bleomycin tends to be
patchy, which probably reflects where bleomycin droplets go,
Fig. 1. Hematoxylin and eosin staining of bleomycin- and saline-treated mouse lung tissue sections. (A and B) Bleomycin-induced fibrosis at day 14, formalin-
fixed sections. Normal focal area of alveolar wall. Thickening with an increase in cells in the interstitium, most of which have spindle morphology typical of
fibroblasts. Admixed within this are inflammatory cells including macrophages. (A) Magnification 100; (B) magnification 400. (C) Negative control (saline
induced) at day 14, formalin-fixed sections. No significant abnormalities in the lung architecture. Magnification 100.
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was fairly intense and widespread (Figs. 1A and B). The
saline-treated lung appears completely normal (Fig. 1C).
Immunohistochemistry
There was no difference in the degree and intensity of
staining of p53 and PCNA from the bleomycin-induced
fibrosis lung sections compared to the saline-induced non-
fibrotic lung tissue section (Figs. 2C–F). The degree of
staining of p27 is the same in fibrotic tissue compared to the
nonfibrotic but the intensity is higher (Figs. 2G and H). It is
quite difficult to explain why since this could be an
experimental artifact or that actually more cells are express-
ing or stabilizing more p27 following the bleomycin injury or
disease. Although no difference in nuclear p21 expression
was found, the level of cytoplasmic p21 expression (both
degree and intensity of staining) is higher in the bronchiolar
and alveolar regions in the fibrotic lung compared to the
nonfibrotic lung tissue sections (Figs. 2A and B).
Gene expression analysis
The gene expression data for p21, p53, PCNA, and CC10
are shown in Table 2. From the data, it can be seen that p53
and PCNA did not change significantly from the fibrotic
lungs generated by bleomycin-treated lungs at days 7 and 14
compared to the negative control, saline-treated lung. Two
CC10 markers have been used, only one of which gave asignificant result in the fibrotic lung at day 7. Thus, no
significant conclusion can be obtained from the CC10 results.
An interesting result was obtained regarding p21 expres-
sion. The levels of p21 expression in fibrotic lung at 14 days
were significantly higher (P = 0.05) when compared to the
negative fibrotic lung. These data fit quite well with the
results obtained by immunohistochemistry (Fig. 2), whereby
p21 expression was found to be higher in the bleomycin-
injured lungs at day 14 compared to the negative fibrotic
lung. From the immunohistochemistry studies, there was no
variation in the levels of p53 and PCNA.Discussion
Bleomycin, a potent cancer chemotherapeutic agent,
causes fibrogenic lung disease in rats and mice similar to
that seen in human subjects. Bleomycin affects many cellular
pathways, but it is believed that the cytotoxic effect is due to
its ability to bind and cleave DNA (Mori et al., 1989). A
number of reports indicate that bleomycin generates reactive
oxygen species in vitro (Daly et al., 1997, 1998; Mori et al.,
1989; Wu et al., 1998b; Yi et al., 1998).
The p53 tumor suppressor protein is a DNA damage-
inducible protein (Albrechtsen et al., 1999; Ashcroft and
Vousden, 1999; Brambilla and Brambilla, 1997; Kaelin,
1999a,b; Lane, 1992; Lakin and Jackson, 1999; Matlashew-
shi, 1999; May and May, 1999; Sheikh et al., 1997; Sigal
and Rotter, 2000; Vogelstein et al., 2000; Wu et al., 1998a;
Fig. 2. Immunohistochemistry of bleomycin- and saline-treated mouse tissue sections. (A and B) p21 immunohistochemistry using AlexaTM 546-conjugated
secondary antibody. Nuclear and cytoplasmic staining present in both alveolar and bronchiolar epithelial regions. p21 expression is greater in the fibrotic lung
(A) and nonfibrotic lung (B). (C and D) p53 immunohistochemistry using AlexaTM 488-conjugated secondary antibody. Cytoplasmic staining present in both
alveolar and bronchiolar epithelial regions in both fibrotic (C) and nonfibrotic lungs (D). (E and F) PCNA immunohistochemistry using AlexaTM 546-
conjugated secondary antibody. Nuclear and cytoplasmic staining present in both alveolar and bronchiolar epithelial regions. No difference between fibrotic (E)
and nonfibrotic (F) lungs. (G and H) p27 immunohistochemistry using AlexaTM 488-conjugated secondary antibody. Nuclear and cytoplasmic staining present
in both alveolar and epithelial regions. An increase p27 expression in fibrotic (G) compared to nonfibrotic lungs (H). (I) Typical negative control whereby the
primary antibody was omitted. Original magnification 100.
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expect to find an increase in p53 expression in bleomycin-
induced fibrosis model. In the bleomycin-induced fibrosis
mouse model, there was no difference in the degree and
intensity of staining of p53 in the fibrosis (at day 14) and
nonfibrotic tissue sections. In the gene expression analysis,
no statistically significant changes in the p53 expression
were found in fibrotic lungs generated by bleomycin-treated
lung at days 7 and 14 compared to the nonfibrotic lungs.
Mishra et al. (2000) found that there was an increase p53
immunostaining in the lung cells of bleomycin-induced
fibrosis tissue at days 3 and 7 but a decrease in day 9 and no
evidence of p53 expression at day 14.In this study, no differences were found in the
immunostaining of PCNA from the fibrotic (day 14) to
nonfibrotic tissue. Also the degree of PCNA expression as
determined by gene expression analysis was the same in
fibrotic lungs (at days 7 and 14) and nonfibrotic lungs.
These data were similar to the data by Mishra et al. (2000).
From immunostaining of p21, the level of p21 staining
was found to be higher in fibrotic (day 14) tissue
compared to nonfibrotic tissue. The level of p21 expres-
sion in fibrotic lungs at day 7 was not statistically higher
when compared to the nonfibrotic lungs. At day 14, the
expression of 21 was statistically higher (P = 0.05) when
compared to nonfibrotic lungs. Mishra et al. (2000) found
Table 2






of fibrotic lungs at day 7
P value
(fibrosis at day
7 vs. normal lungs)
RNA levels
in fibrotic
lungs at day 14
P value
(fibrosis at day
14 vs. normal lungs)
p21 U09507 231 392.7 0.12 435.3 0.05
p53 U59758 30.8 25.0 0.77 66.7 0.31
p53 X01237 187.2 146.7 0.57 162.3 0.74
PCNA AA146128 20.0 13.3 0.42 20.0 1
PCNA X57800 342.4 409.7 0.57 392.7 0.68
CC10 AA028748 3119.2 3042.7 0.95 3138.0 0.98
CC10 L24372 2282.8 1292.7 0.01 1789.3 0.21
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but the most intense p21 nuclear staining in epithelial cells
was at day 9.
The mRNA levels of p53 and p21 have been studied in
bleomycin-induced fibrosis lungs at 1 h, 6 h, 1, 3, 5, 7, and
14 days by Kuwano et al. (1996, 2000). Kuwano et al.
(2000) found out that lung mRNA levels of p53 and p21
were up-regulated at 1 h to day 7 after bleomycin
instillation, while only p21 mRNA but not p53 mRNA
was detectable at 14 days.
From the above data, it appears that following bleomycin
induction, an increase in p21 induction via p53-dependent
pathways may be involved. Since p53 was mainly induced
in the early phase, it is likely that p53 may have an
important role in the initial phase that is when DNA were
mainly damaged by bleomycin itself but not at a later stage
when DNA are damaged mainly by infiltrating inflamma-
tory cells.p21 is most probably playing an important role in
the p53-induced G1 arrest because it is a potential inhibitor
of cyclin-dependent kinase activity (Cheng et al., 1999;
Haapaja¨rvi et al., 1999; Rousseau et al., 1999; Sheikh et al.,
1997; Tomoda et al., 1999; Wu et al., 1998a). It has been
shown previously that serum or individual growth factors
such as platelet-derived growth factor, fibroblast growth
factor, and epidermal growth factor but not insulin are able
to induce p21 in quiescent p53-deficient cells as well as
normal cells (Michieli et al., 1994). Thus, the induction of
p21 without up-regulation of p53 mRNA at 14 days after
bleomycin-induction may be dependent on growth factors,
such as platelet-derived growth factor and fibroblast growth
factor.
Apart from direct DNA damage from bleomycin and
subsequent cell death, fibrosis could have resulted from
inflammatory cell recruitment, fibroblast proliferation, or
collagen synthesis. Inflammatory cells, including neutro-
phils and monocytes, can release toxic oxygen reactive
species that can damage the DNA (Sato and Muramatsu,
1985; Sato et al., 1999).
Recent evidence suggests that cell–ECM interaction may
be more important in modulating fibrosis than simple the
degree of inflammation (Sheppard, 2001b). Although many
of the normal lung development is still unknown, it is clear
an important part of the network of reciprocal inductive and
inhibitory signals involves the mesenchymal cells, pulmo-nary epithelial cells, and components of the ECM (Ebihara
et al., 2000).
Several lines of evidence suggest that TGF-h is
involved in the regulation of pulmonary fibrosis (Coker
et al., 1996; Gauldie et al., 2002). TGF-h1 has been shown
to be activated via integrins mainly avh6 (Sheppard,
2001a). The binding and activation of latent or inactive
TGF-h1 could be a mechanism whereby pulmonary
fibrosis and inflammation could be regulation (Munger et
al., 1999). It has also been shown that h6 integrin
expression is associated with sites of neutrophil influx in
lung epithelium (Miller et al., 2001).
Mice that are homozygous for a null mutation of the h6
subunit gene phenotypically exhibit pronounced lympho-
cyte accumulation in conducting airways, suggesting that
the avh6 integrin complex may play a role in down-
regulating inflammation in the lung (Huang et al., 1996). h6
knockout mice are protected from development of TGF-h1-
dependent bleomycin-induced pulmonary fibrosis, yet leu-
kocyte recruitment into the lung after treatment with
bleomycin was not inhibited (Munger et al., 1999). This
further suggests the important role of avh6 during
inflammatory events in the airways.
From immunostaining, the degree of p27 staining was
found to be the same but the intensity seems to be higher in
fibrotic (day 14) tissue compared to nonfibrotic tissue. The
increase in the degree of p27 staining could be either due to
probable increase in TGF-h or due to changes in cell–cell
interactions (Llyod et al., 1999; Slingerland and Pagano,
2000). It is quite difficult to make any conclusions about
p27 since the effects of TGF-h, rapamycin, and contact
inhibition on cell proliferation remained unchanged in p27
null mice (Nakayama et al., 1996).
From the gene expression analysis studies, only one
CC10 marker gave a significant result in fibrotic lung at day
7, but no significant conclusion can be made since only one
of the CC10 was statistically significant. A decrease in the
number of Clara cells evaluated by CC10 mRNA expression
in the airway epithelial lining was described at 28 days
following bleomycin induction (Daly et al., 1997). Daly et
al. (1998) suggested that where CC10 mRNA expression
was lost and SPB mRNA remained the same, the cells could
be an intermediate cell type that is a precursor to either
mature Clara cells or ciliated cells.
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p21 expression was found to increase independent of p53
at 14 days after bleomycin induction; thus, other factors
such as cell–cell interactions, cell–integrin interactions,
changes in ECM composition, and time scale could
determine the expression of p21.
Since p21 is known to be involved in cell proliferation,
death, and differentiation, it is important to study p21
expression in a progenitor cell type such as Clara cells. p21
was found to be expressed both in the cytoplasm and in the
nucleus. From the literature, little is know about the
functional role of cytoplasmic p21; thus, further studies
need to be carried out to determine its role in lung injury and
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